Long-term, Non-interventional Study of Recipients of Yescarta® for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, and Follicular Lymphoma

First published 06/12/2019

Last updated 31/07/2024

EU PAS number:

EUPAS32539

Study

Ongoing

Documents

Study protocol

Initial protocol

KT-EU-471-0117-appendix-16.1.1-protocol amendment 3_f-redact_reducedsize

English (4.76 MB - PDF)View document

Updated protocol

KT-EU-471-0117-appendix-16.1.1-protocol amendment 5_f-redact_reducedsize

First published: 22/02/2024

English (9.98 MB - PDF)View document

Study results

Study report

Other information

Secondary tabs